Contribution seq 15308

Payload

{
  "excerpt": "Clinical response data covered the full treatment history, although records before enrolment were acknowledged to be less accurate and comprehensive than post-enrolment information. We evaluated the predictive power of the IMFs in the second-line mCRPC setting, in which patients commonly transition empirically between ARPIs and taxanes following first-line therapy. Our analysis focused on these two common therapy types, aiming to move beyond the conventional sequential switching paradigm toward a precision, biomarker-guided approach to therapy selection at second line. No significant differences in TTF were observed between these two therapies (Extended Data Fig. 9), supporting the use of biomarker-positive versus biomarker-negative comparisons to evaluate predictive capacity in this setting.",
  "locator": {},
  "source_id": "79584d57-99fb-8fd2-9158-ef0a181c1bc3",
  "excerpt_hash": "sha256:bf8e820797eed36845f4abc891794394f1046787c7062f243f71bc8d7de7db38",
  "locator_type": "QUOTE"
}

Rows created

• SourceLocation 4a9c2eb6-a9e4-80e2-a50e-85c5c153e9be

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}